Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped up prior to trading on Monday . The stock had previously closed at $21.30, but opened at $23.15. Ascentage Pharma Group International shares last traded at $23.5530, with a volume of 973 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on AAPG shares. Oppenheimer assumed coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target on the stock. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. BTIG Research reiterated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Thursday, March 26th. Finally, Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $48.00.

Ascentage Pharma Group International Trading Up 10.1%

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The company’s 50-day moving average is $23.90 and its two-hundred day moving average is $29.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million during the quarter.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several large investors have recently bought and sold shares of the stock. Tema Etfs LLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth $610,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International during the third quarter valued at about $96,000. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the third quarter valued at about $383,000. UBS Group AG boosted its holdings in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International in the 2nd quarter worth about $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.